Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM (SEQUOIA-HCM) (SEQUOIA-HCM)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05186818 |
|
Recruitment Status :
Completed
First Posted : January 11, 2022
Last Update Posted : January 8, 2024
|
Sponsor:
Cytokinetics
Collaborator:
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Information provided by (Responsible Party):
Cytokinetics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | December 1, 2023 |
| Actual Study Completion Date : | December 1, 2023 |